Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp online chat

	NCI Highlights


	Maintenance Rituximab for Follicular Lymphoma Azacitidine Improves Survival in MDS Second Stem Cell Transplant Not Helpful in Myeloma

	Related Links


	Educational Materials About Clinical Trials Clinical Trials: Questions and Answers Questions to Ask Your Doctor Drug Information from MedlinePlus

Assessment of Treatment Response Using PET/CT Scanner - Non Hodgkin's Lymphoma

Basic Trial Information
Trial Description
Summary
Eligibility Criteria
Trial Contact Information

Basic Trial Information

Phase Type Status Age Sponsor Protocol IDs
Phase II Diagnostic, Treatment Active 18 and over Other UHN REB 05-0339-C
NCT00188929

Trial Description

Summary

In this study the treatment process will be closely monitored using a novel imaging technology, a PET/CT scanner. PET stands for Positron Emission Tomography and in this case it will be combined with a conventional x-ray Computerized Tomography (CT) scan. This is not a study of any particular form of treatment. The treatment you receive will be the most appropriate standard treatment whether you are in the study or not.

The goal of radiation therapy is to deliver a given amount of radiation dose to the area where there is a lymphoma tumour. We are doing this study to see which part of the tumour reacts to the radiation treatment, and which part does not react, by monitoring the progress of your treatment with a combined PET/CT scan. In particular, changes of the size and shape of the tumour that occur during the treatment can be detected and will be visible on the images. These images will be thoroughly analysed. The ability of the PET/CT scanner to detect these changes during a course of radiation treatment will be the subject of this study. We will also be able to see if this information will eventually relate to or predict whether lymphoma tumours will be completely eradicated by the treatment.

Eligibility Criteria

Inclusion Criteria:

Histologic diagnosis of NHL:Any histology

Stage I-IV

Measurable disease by CT scan (gross disease measuring at least 2 cm in any one dimension)

Planned radiation dose prescription >=30 gy, >=20 fractions, >=3weeks duration

Informed consent

Previous chemotherapy is allowed, provided the above eligibility criteria are me

Exclusion Criteria:

To minimize effect from breathing motion, patients presenting with parenchymal lung tumours and tumours involving liver and stomach will be excluded

Concurrent systemic chemotherapy (glucocorticoids when used alone is allowed)

Trial Contact Information

Trial Lead Organizations/Sponsors

Toronto Western Hospital

Princess Margaret Hospital

Richard Tsang, MD

Principal Investigator

Richard Tsang, MD		Ph: 416-946-2121
		Email: richard.tsang@rmp.uhn.on.ca

Trial Sites

Canada

Ontario

Toronto

Princess Margaret Hospital

Richard Tsang, MD Ph: 416-946-2121

Email: richard.tsang@rmp.uhn.on.ca

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00188929
Information obtained from ClinicalTrials.gov on March 18, 2009

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.